A5071733391- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Psychosomatic Disorders and Their Treatments
- Memory and Neural Mechanisms
- Firm Innovation and Growth
- Mental Health and Psychiatry
- Schizophrenia research and treatment
- Health, Environment, Cognitive Aging
- Health and Well-being Studies
- Autism Spectrum Disorder Research
- Health Systems, Economic Evaluations, Quality of Life
- Labor market dynamics and wage inequality
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Parkinson's Disease Mechanisms and Treatments
- Diet and metabolism studies
Lund University
2017-2023
Helsingborgs lasarett
2019-2023
The Memory Clinic
2021
Linköping University Hospital
2014
Infineon Technologies (Germany)
2003
Abstract Mild behavioral impairment (MBI) is suggested as risk marker for neurodegenerative diseases, such Alzheimer’s disease (AD). Recently, pathologic tau deposition in the brain has been shown closely related to clinical manifestations, cognitive deficits. Yet, associations between pathology and MBI have rarely investigated. It further debated if precedes deficits AD. Here, we explored potential mechanisms by which AD, this studying preclinical In all, 50 amyloid-β-positive cognitively...
BackgroundThe impact of Alzheimer's disease (AD) pathology and cognitive deficits on longitudinal neuropsychiatric symptoms is unclear, especially in early stages.MethodsCognitively unimpaired older adults (N = 356) enrolled the prospective Swedish BioFINDER study were examined. Neuropsychiatric assessments encompassed Apathy Evaluation Scale Hospital Anxiety Depression Scale, performed biennially (together with tests global cognition) for up to 8 years. Biomarkers measured cerebrospinal...
Abstract The amygdala was highlighted as an early site for neurofibrillary tau tangle pathology in Alzheimer’s disease the seminal 1991 article by Braak and Braak. This knowledge has, however, only received traction recently with advances imaging image analysis techniques. Here, we provide a cross-disciplinary overview of neuroimaging studies on amygdala. These strong support role utility biomarkers detecting changes predicting decline cognitive functions neuropsychiatric symptoms stages. We...
Objective The clinical phenotype of the rare behavioural variant Alzheimer’s disease (bvAD) is insufficiently understood. Given strong clinico-anatomical correlations tau pathology in AD, we investigated distribution deposits bvAD, in-vivo and ex-vivo, using positron emission tomography (PET) postmortem examination. Methods For PET study, seven amyloid-β positive bvAD patients underwent [ 18 F]flortaucipir or F]RO948 PET. We converted uptake values into standardised (W-)scores, adjusting for...
Abstract Background In Alzheimer´s disease (AD), the emergence of cortical tau deposition has been related to clinical onset symptoms. However, associations between and Mild Behavioral Impairment (MBI), defined as a neurobehavioral syndrome characterized by late life development neuropsychiatric symptoms (Table 1), have rarely investigated. It is unclear if MBI precedes cognitive symptoms, which manifestation best predicts neuropathology in AD. We cross‐sectionally explored tau‐pathology AD...
Background: Apathy, a prevalent and clinically relevant symptom in neurodegenerative disease, is often evaluated by the instrument Apathy Evaluation Scale (AES). However, this has not been translated into Swedish, halting clinical research efforts. Furthermore, previous studies lack analyses of some basic properties, such as legitimacy total score, or have analysed dimensionality questionable methods.Aim: To translate psychometrically evaluate Swedish version AES.Method: The AES was...
ABSTRACT Objective The clinical phenotype of the rare behavioral variant Alzheimer’s disease (bvAD) is insufficiently understood. Given strong clinico-anatomical correlations tau pathology in AD, we investigated distribution deposits bvAD, in-vivo and ex-vivo , using PET postmortem examination. Methods For study, seven amyloid-P positive bvAD patients underwent [ 18 F]flortaucipir or F]RO948 PET. We converted uptake values into standardized (W-)scores, by adjusting for age, sex MMSE a...
Abstract Background A distinct subset of patients with Alzheimer’s disease (AD) experience early and predominant behavioral personality changes, while the neurobiological origins these symptoms are largely unknown. In this study, we examined distribution tau pathology using PET imaging or post‐mortem evaluation in variant AD (bvAD). Method For seven amyloid‐β positive clinically diagnosed bvAD from Amsterdam Dementia Cohort (ADC, n=2), University California San Francisco (UCSF, n=3) Swedish...
Abstract Background A better understanding of drivers behind neuropsychiatric symptoms (NPS) in neurocognitive diseases, such as Alzheimer’s disease, can potentially guide drug development. Cross‐sectional studies have related apathy, depression and anxiety to beta‐amyloid‐ (Aβ) tau‐pathology, neurodegeneration well cognitive deficits already at preclinical stages. However, longitudinal are scarce often small. We investigated effects neuropathology cognition on the trajectories NPS a large...
Early clinical risk markers of neurodegenerative diseases, such as Alzheimer’s disease (AD), can be considered fundamental in a new era with novel modifying treatments on the horizon. Mild Behavioral Impairment (MBI) is diagnostic construct defined by later-life emergence persistent neuropsychiatric symptoms (e.g. apathy, anxiety, depression, amongst others) displayed older adults, aim to identify individuals at increased future dementia. According established MBI criteria syndrome co-occur...